477 related articles for article (PubMed ID: 11812148)
1. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE
J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148
[TBL] [Abstract][Full Text] [Related]
2. Association of alpha-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR.
Ramakrishnan M; Jensen PH; Marsh D
Biochemistry; 2006 Mar; 45(10):3386-95. PubMed ID: 16519533
[TBL] [Abstract][Full Text] [Related]
3. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
[TBL] [Abstract][Full Text] [Related]
4. Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein.
Choi W; Zibaee S; Jakes R; Serpell LC; Davletov B; Crowther RA; Goedert M
FEBS Lett; 2004 Oct; 576(3):363-8. PubMed ID: 15498564
[TBL] [Abstract][Full Text] [Related]
5. Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant.
Wersinger C; Vernier P; Sidhu A
Biochemistry; 2004 Feb; 43(5):1242-53. PubMed ID: 14756560
[TBL] [Abstract][Full Text] [Related]
6. Structural determinants of PLD2 inhibition by alpha-synuclein.
Payton JE; Perrin RJ; Woods WS; George JM
J Mol Biol; 2004 Apr; 337(4):1001-9. PubMed ID: 15033366
[TBL] [Abstract][Full Text] [Related]
7. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro.
Hoyer W; Cherny D; Subramaniam V; Jovin TM
Biochemistry; 2004 Dec; 43(51):16233-42. PubMed ID: 15610017
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
[TBL] [Abstract][Full Text] [Related]
9. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Conway KA; Harper JD; Lansbury PT
Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
[TBL] [Abstract][Full Text] [Related]
10. A novel mechanism of interaction between alpha-synuclein and biological membranes.
Kim YS; Laurine E; Woods W; Lee SJ
J Mol Biol; 2006 Jul; 360(2):386-97. PubMed ID: 16762368
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70.
Albani D; Peverelli E; Rametta R; Batelli S; Veschini L; Negro A; Forloni G
FASEB J; 2004 Nov; 18(14):1713-5. PubMed ID: 15345691
[TBL] [Abstract][Full Text] [Related]
12. Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease.
Flower TR; Chesnokova LS; Froelich CA; Dixon C; Witt SN
J Mol Biol; 2005 Sep; 351(5):1081-100. PubMed ID: 16051265
[TBL] [Abstract][Full Text] [Related]
13. Binding of Cu(II) to human alpha-synucleins: comparison of wild type and the point mutations associated with the familial Parkinson's disease.
Hong L; Simon JD
J Phys Chem B; 2009 Jul; 113(28):9551-61. PubMed ID: 19548659
[TBL] [Abstract][Full Text] [Related]
14. alpha-Synuclein membrane interactions and lipid specificity.
Jo E; McLaurin J; Yip CM; St George-Hyslop P; Fraser PE
J Biol Chem; 2000 Nov; 275(44):34328-34. PubMed ID: 10915790
[TBL] [Abstract][Full Text] [Related]
15. Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity.
Li W; Lee MK
J Neurochem; 2005 Jun; 93(6):1542-50. PubMed ID: 15935070
[TBL] [Abstract][Full Text] [Related]
16. Alpha-synuclein association with phosphatidylglycerol probed by lipid spin labels.
Ramakrishnan M; Jensen PH; Marsh D
Biochemistry; 2003 Nov; 42(44):12919-26. PubMed ID: 14596606
[TBL] [Abstract][Full Text] [Related]
17. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence studies suggest a role for alpha-synuclein in the phosphatidylinositol lipid signaling pathway.
Narayanan V; Guo Y; Scarlata S
Biochemistry; 2005 Jan; 44(2):462-70. PubMed ID: 15641770
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein selectively binds to anionic phospholipids embedded in liquid-disordered domains.
Stöckl M; Fischer P; Wanker E; Herrmann A
J Mol Biol; 2008 Feb; 375(5):1394-404. PubMed ID: 18082181
[TBL] [Abstract][Full Text] [Related]
20. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
Li J; Uversky VN; Fink AL
Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
